Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kornmann, M.
Right arrow Articles by Link, K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kornmann, M.
Right arrow Articles by Link, K. H.
Clinical Cancer Research Vol. 9, 4116-4124, September 15, 2003
© 2003 American Association for Cancer Research


Clinical Trials

Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression Levels

Predictors for Survival in Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil1

Marko Kornmann2, Wolfgang Schwabe, Silvia Sander, Martina Kron, Jörn Sträter, Sucan Polat, Erika Kettner, Hans F. Weiser, Wolfram Baumann, Harald Schramm, Peter Häusler, Kati Ott, Detlev Behnke, Ludger Staib, Hans G. Beger and Karl H. Link

Departments of General Surgery [M. Ko., S. P., L. S., H. G. B., K. H. L.], Biometry and Medical Documentation [S. S., M. Kr.], and Pathology [J. S.], University of Ulm, 89075 Ulm; Oncoscreen Research Institute, 07745 Jena [W. S., P. H., K. O., D. B.]; Department of Medicine, Städtisches Klinikum, 39002 Magdeburg [E. K.]; Department of Surgery I, Diakoniekrankenhaus, 27356 Rotenburg/Wümme [H. F. W.]; Department of General Surgery, Klinik am Eichert, 73035 Göppingen [W. B.]; and Department of Surgery, Wald-Klinikum 27548 Gera [H. S.], Germany

Purpose: Despite adjuvant 5-fluorouracil (5-FU) therapy, ~30% of patients with International Union against Cancer stage II and III colorectal cancer develop recurrence. In this study, we determined the prognostic value of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression in colorectal cancer patients treated with adjuvant 5-FU.

Experimental Design: A real-time reverse transcription-PCR technique for quantitation of relative gene expression from paraffin-embedded specimen was established first. In a second step, archival paraffin-embedded primary tumor tissue of 309 patients who participated in adjuvant colorectal cancer trials was analyzed for TS and DPD mRNA expression.

Results: TS mRNA expression determined by real-time reverse transcription-PCR correlated with TS protein levels determined by TS immunoblot and immunohistochemistry in cultured colon cancer cell lines and paraffin-embedded primary tumor tissue. TS mRNA levels in fresh-frozen tissues also correlated with TS mRNA levels in corresponding paraffin sections. Among the patients receiving adjuvant 5-FU therapy, those with high TS survived longer than those with low TS, and in each TS subgroup, the ones with low DPD survived longer than the ones with high DPD levels. Multiple Cox regression analysis showed that besides tumor stage (P = 0.010), only the combination of TS and DPD expression turned out to be an independent prognostic factor for survival (P = 0.030).

Conclusions: This suggests that TS and DPD quantitation may be helpful to evaluate prognosis of patients receiving adjuvant 5-FU and that patients with high TS and low DPD may benefit from adjuvant 5-FU chemotherapy.




This article has been cited by other articles:


Home page
Ann OncolHome page
R. Soong, N. Shah, M. Salto-Tellez, B. C. Tai, R. A. Soo, H. C. Han, S. S. Ng, W. L. Tan, N. Zeps, D. Joseph, et al.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
Ann. Onc., May 1, 2008; 19(5): 915 - 919.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. Krugluger, A. Brandstaetter, E. Kallay, J. Schueller, E. Krexner, S. Kriwanek, E. Bonner, and H. S. Cross
Regulation of Genes of the Circadian Clock in Human Colon Cancer: Reduced Period-1 and Dihydropyrimidine Dehydrogenase Transcription Correlates in High-Grade Tumors
Cancer Res., August 15, 2007; 67(16): 7917 - 7922.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Del Rio, F. Molina, C. Bascoul-Mollevi, V. Copois, F. Bibeau, P. Chalbos, C. Bareil, A. Kramar, N. Salvetat, C. Fraslon, et al.
Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan
J. Clin. Oncol., March 1, 2007; 25(7): 773 - 780.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Liersch, C. Langer, B. M. Ghadimi, B. Kulle, D. E. Aust, G. B. Baretton, W. Schwabe, P. Hausler, H. Becker, and C. Jakob
Lymph Node Status and TS Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based Chemoradiotherapy
J. Clin. Oncol., September 1, 2006; 24(25): 4062 - 4068.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, C. Shi, K. Danenberg, P. V. Danenberg, H. Kuramochi, et al.
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Clin. Cancer Res., August 1, 2006; 12(15): 4652 - 4661.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. Andre, D. Sargent, J. Tabernero, M. O'Connell, M. Buyse, A. Sobrero, J.-L. Misset, C. Boni, and A. de Gramont
Current Issues in Adjuvant Treatment of Stage II Colon Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 887 - 898.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Langer, K. Specht, K. Becker, P. Ewald, M. Bekesch, M. Sarbia, R. Busch, M. Feith, H. J. Stein, J.-R. Siewert, et al.
Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett Carcinoma
Clin. Cancer Res., October 15, 2005; 11(20): 7462 - 7469.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. L. Westra, H. Hollema, M. Schaapveld, I. Platteel, K. A. Oien, W. N. Keith, R. Mauritz, G. J. Peters, C. H. C. M. Buys, R. M. W. Hofstra, et al.
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients
Ann. Onc., October 1, 2005; 16(10): 1646 - 1653.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. J. Epstein
Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment
Clin. Cancer Res., August 1, 2005; 11(15): 5337 - 5341.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Jakobsen, J. N. Nielsen, N. Gyldenkerne, and J. Lindeberg
Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal Tissue As Predictors of Fluorouracil Sensitivity
J. Clin. Oncol., March 1, 2005; 23(7): 1365 - 1369.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. A. Meyerhardt and R. J. Mayer
Systemic Therapy for Colorectal Cancer
N. Engl. J. Med., February 3, 2005; 352(5): 476 - 487.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.